NeOnc Technologies schedules FDA end-of-Phase 1 meeting for brain cancer drug NEO212

• NeOnc Technologies scheduled an in-person FDA End-of-Phase 1 meeting for NEO212 on Nov. 17, 2026.
• Phase 1 results were already reported; the company flagged durable disease control in two heavily pretreated brain cancer patients.
• Management framed the outcome as supportive of advancing NEO212 into Phase 2 and pursuing a registrational strategy.
• FDA feedback will guide a revised Phase 2 plan, including patient population and endpoints, with no assurance of accelerated approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609280800PRIMZONEFULLFEED9834748) on September 28, 2026, and is solely responsible for the information contained therein.